# DESCRIPTION

## INTRODUCTION

## SUMMARY

## DESCRIPTION

### Definitions

### MEWS WVFLFFLSVTTGVHS (SEQ ID NO:40).

### Antibody Combination

### Pharmaceutical Compositions

### Methods of Treatment

## EXAMPLES

### Example 1. STI-6643 Demonstrates Drastically Reduced Hemagglutination as Compared to Competitor Antibody Hu5F9

### Example 2. STI-6643 Blocks Human CD47/SIRPÎ± Interaction in a Dose-Dependent Manner

### Example 3. STI-6643 Promotes Phagocytosis of Tumor Cells in a Dose-Dependent Manner

### Example 4. STI-6643 Improves Rituximab-induced Phagocytosis When Combined at Suboptimal Doses

### Example 5. STI-6643 Shows Comparable Anti-Tumor Activity Than Hu5F9 in a Preclinical Mouse Model

### Example 6. Combination of STI-6643 and Rituximab Improves Anti-Tumor Activity and Prolonged Survival

### Example 7. STI-6643 is Well Tolerated and Safe in Non-Human Primates at 150 mg/kg

### Example 8. Anti-CD47 Clone STI-6643 Shows Preferential Binding to Tumor Cells. Binding Assay on Mixed-Cell Samples

### Example 9. STI-6643 Drastically Reduces Hemagglutination as Compared to Competitor Antibody Hu5F9 (Additional Hemagglutination Experiment)

